Millon Behavioral Medicine Diagnostic (MBMD) predicts health-related quality of life (HrQoL) over time among men treated for localized prostate cancer

Dean G. Cruess, Catherine Benedict, Emily G. Lattie, Ivan Molton, Dave Kinsinger, Bruce Kava, Murugesan Manoharan, Mark Soloway, Frank J. Penedo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Prostate cancer treatment presents multiple challenges that can negatively affect health-related quality of life (HrQoL), and that can be further compromised by maladaptive personality styles and psychological adjustment difficulties. This study examined the utility of a comprehensive psychosocial screening tool to identify psychosocial traits that prospectively predict HrQoL status among men treated for localized prostate cancer. The Millon Behavioral Medicine Diagnostic (MBMD) was administered to 66 men (M age = 68 years, 59% White) treated by either radical prostatectomy or radiotherapy along with standard measures of general and prostate-cancer-specific quality of life assessed at a 12-month follow-up. Higher scores on both summary MBMD Management Guides (Adjustment Difficulties and Psych Referral) and higher scores on personality styles characterized by avoidance, dependency, depression, passive aggressiveness, and self-denigration predicted lower HrQoL (β range =-.21 to-.50). Additionally, higher scores on the MBMD Depression, Tension-Anxiety, and Future Pessimism scales predicted lower HrQoL. Finally, higher scores on the MBMD Intervention Fragility and Utilization Excess scale also consistently predicted poorer mental and physical health functioning over time. These results point to the utility of the MBMD to help screen for potential impairments in mental and physical health functioning in men undergoing treatment for prostate cancer.

Original languageEnglish
Pages (from-to)54-61
Number of pages8
JournalJournal of Personality Assessment
Volume95
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Behavioral Medicine
Prostatic Neoplasms
Quality of Life
Personality
Mental Health
Depression
Social Adjustment
Prostatectomy
Radiotherapy
Referral and Consultation
Anxiety
Medicine
Diagnostics
Health
Prostate Cancer
Therapeutics

ASJC Scopus subject areas

  • Clinical Psychology
  • Arts and Humanities (miscellaneous)

Cite this

Millon Behavioral Medicine Diagnostic (MBMD) predicts health-related quality of life (HrQoL) over time among men treated for localized prostate cancer. / Cruess, Dean G.; Benedict, Catherine; Lattie, Emily G.; Molton, Ivan; Kinsinger, Dave; Kava, Bruce; Manoharan, Murugesan; Soloway, Mark; Penedo, Frank J.

In: Journal of Personality Assessment, Vol. 95, No. 1, 01.01.2013, p. 54-61.

Research output: Contribution to journalArticle

Cruess, Dean G. ; Benedict, Catherine ; Lattie, Emily G. ; Molton, Ivan ; Kinsinger, Dave ; Kava, Bruce ; Manoharan, Murugesan ; Soloway, Mark ; Penedo, Frank J. / Millon Behavioral Medicine Diagnostic (MBMD) predicts health-related quality of life (HrQoL) over time among men treated for localized prostate cancer. In: Journal of Personality Assessment. 2013 ; Vol. 95, No. 1. pp. 54-61.
@article{c987fd86ac1847e7952b25de0b10a786,
title = "Millon Behavioral Medicine Diagnostic (MBMD) predicts health-related quality of life (HrQoL) over time among men treated for localized prostate cancer",
abstract = "Prostate cancer treatment presents multiple challenges that can negatively affect health-related quality of life (HrQoL), and that can be further compromised by maladaptive personality styles and psychological adjustment difficulties. This study examined the utility of a comprehensive psychosocial screening tool to identify psychosocial traits that prospectively predict HrQoL status among men treated for localized prostate cancer. The Millon Behavioral Medicine Diagnostic (MBMD) was administered to 66 men (M age = 68 years, 59{\%} White) treated by either radical prostatectomy or radiotherapy along with standard measures of general and prostate-cancer-specific quality of life assessed at a 12-month follow-up. Higher scores on both summary MBMD Management Guides (Adjustment Difficulties and Psych Referral) and higher scores on personality styles characterized by avoidance, dependency, depression, passive aggressiveness, and self-denigration predicted lower HrQoL (β range =-.21 to-.50). Additionally, higher scores on the MBMD Depression, Tension-Anxiety, and Future Pessimism scales predicted lower HrQoL. Finally, higher scores on the MBMD Intervention Fragility and Utilization Excess scale also consistently predicted poorer mental and physical health functioning over time. These results point to the utility of the MBMD to help screen for potential impairments in mental and physical health functioning in men undergoing treatment for prostate cancer.",
author = "Cruess, {Dean G.} and Catherine Benedict and Lattie, {Emily G.} and Ivan Molton and Dave Kinsinger and Bruce Kava and Murugesan Manoharan and Mark Soloway and Penedo, {Frank J.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1080/00223891.2012.681819",
language = "English",
volume = "95",
pages = "54--61",
journal = "Journal of Personality Assessment",
issn = "0022-3891",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Millon Behavioral Medicine Diagnostic (MBMD) predicts health-related quality of life (HrQoL) over time among men treated for localized prostate cancer

AU - Cruess, Dean G.

AU - Benedict, Catherine

AU - Lattie, Emily G.

AU - Molton, Ivan

AU - Kinsinger, Dave

AU - Kava, Bruce

AU - Manoharan, Murugesan

AU - Soloway, Mark

AU - Penedo, Frank J.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Prostate cancer treatment presents multiple challenges that can negatively affect health-related quality of life (HrQoL), and that can be further compromised by maladaptive personality styles and psychological adjustment difficulties. This study examined the utility of a comprehensive psychosocial screening tool to identify psychosocial traits that prospectively predict HrQoL status among men treated for localized prostate cancer. The Millon Behavioral Medicine Diagnostic (MBMD) was administered to 66 men (M age = 68 years, 59% White) treated by either radical prostatectomy or radiotherapy along with standard measures of general and prostate-cancer-specific quality of life assessed at a 12-month follow-up. Higher scores on both summary MBMD Management Guides (Adjustment Difficulties and Psych Referral) and higher scores on personality styles characterized by avoidance, dependency, depression, passive aggressiveness, and self-denigration predicted lower HrQoL (β range =-.21 to-.50). Additionally, higher scores on the MBMD Depression, Tension-Anxiety, and Future Pessimism scales predicted lower HrQoL. Finally, higher scores on the MBMD Intervention Fragility and Utilization Excess scale also consistently predicted poorer mental and physical health functioning over time. These results point to the utility of the MBMD to help screen for potential impairments in mental and physical health functioning in men undergoing treatment for prostate cancer.

AB - Prostate cancer treatment presents multiple challenges that can negatively affect health-related quality of life (HrQoL), and that can be further compromised by maladaptive personality styles and psychological adjustment difficulties. This study examined the utility of a comprehensive psychosocial screening tool to identify psychosocial traits that prospectively predict HrQoL status among men treated for localized prostate cancer. The Millon Behavioral Medicine Diagnostic (MBMD) was administered to 66 men (M age = 68 years, 59% White) treated by either radical prostatectomy or radiotherapy along with standard measures of general and prostate-cancer-specific quality of life assessed at a 12-month follow-up. Higher scores on both summary MBMD Management Guides (Adjustment Difficulties and Psych Referral) and higher scores on personality styles characterized by avoidance, dependency, depression, passive aggressiveness, and self-denigration predicted lower HrQoL (β range =-.21 to-.50). Additionally, higher scores on the MBMD Depression, Tension-Anxiety, and Future Pessimism scales predicted lower HrQoL. Finally, higher scores on the MBMD Intervention Fragility and Utilization Excess scale also consistently predicted poorer mental and physical health functioning over time. These results point to the utility of the MBMD to help screen for potential impairments in mental and physical health functioning in men undergoing treatment for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84872017081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872017081&partnerID=8YFLogxK

U2 - 10.1080/00223891.2012.681819

DO - 10.1080/00223891.2012.681819

M3 - Article

C2 - 22571442

AN - SCOPUS:84872017081

VL - 95

SP - 54

EP - 61

JO - Journal of Personality Assessment

JF - Journal of Personality Assessment

SN - 0022-3891

IS - 1

ER -